6OP.F OSE IMMUNOTHERAPE.EO -20
- Market cap
- EUR 41.5M
- P/E
- -
- P/B
- 1.47x
- ROE
- -135.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6OP.F undervalued?
Graham numberThe Graham number of OSE IMMUNOTHERAPE.EO -20 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
OSE IMMUNOTHERAPE.EO -20 fundamental analysis
No fundamental analysis for OSE IMMUNOTHERAPE.EO -20 yet.
OSE IMMUNOTHERAPE.EO -20 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About OSE IMMUNOTHERAPE.EO -20
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. The company's products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE…
Full company profileOSE IMMUNOTHERAPE.EO -20 financial statements
OSE IMMUNOTHERAPE.EO -20 annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 26.3M | 18.3M | 2.23M | 69.9M | 2.62M |
| Operating Income | -16.6M | -18.4M | -23.1M | 43.6M | -36.6M |
| EBITDA | - | -13.1M | -17.5M | 46.3M | -31.3M |
| Net Income | -16.9M | -17.8M | -23.0M | 37.4M | -37.7M |
| EPS | -0.91 | -0.96 | -1.07 | 1.71 | -1.68 |
| Balance Sheet | |||||
| Total Assets | 102M | 91.8M | 82.1M | 124M | 78.9M |
| Total Liabilities | 54.0M | 59.1M | 59.1M | 60.1M | 51.1M |
| Shareholders' Equity | 47.9M | 32.7M | 23.0M | 63.8M | 27.8M |
| Cash & Short-term Investments | 33.6M | 25.6M | 18.7M | 16.7M | 17.6M |
| Cash Flow | |||||
| Operating Cash Flow | -9.92M | -18.3M | -19.8M | 48.4M | -34.0M |
| Capital Expenditure | 472K | 274K | 16.0K | 77.0K | 98.0K |
| Free Cash Flow | -10.4M | -18.5M | -19.8M | 48.4M | -34.1M |
| Ratios | |||||
| ROE | -35.2% | -54.4% | -100.1% | 58.7% | -135.8% |
| ROA | -16.5% | -19.4% | -28.0% | 30.2% | -47.8% |
| Net Profit Margin | -64.1% | -97.0% | -1,032.9% | 53.6% | -1,439.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
OSE IMMUNOTHERAPE.EO -20 dividends
OSE IMMUNOTHERAPE.EO -20 has not paid dividends in the last 5 fiscal years.
Who owns OSE IMMUNOTHERAPE.EO -20
- Insiders 25.38%
- Institutions 2.70%
- Public & others 71.92%
- Shares outstanding 24.7M
- Free float 17.3M
OSE IMMUNOTHERAPE.EO -20 company profile
- Company name
- OSE IMMUNOTHERAPE.EO -20
- Ticker
- 6OP.F
- ISIN
- FR0012127173
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 64
- Fiscal year end
- December
- Address
- 22, boulevard Benoni Goulin, Nantes, France, 44200
- Phone
- 33 2 28 29 10 10
- Website
- ose-immuno.com
About OSE IMMUNOTHERAPE.EO -20
OSE Immunotherapeutics SA, a clinical-stage biotechnology company, develops immunotherapies in the areas of immune-oncology and immune-inflammation in France and internationally. The company's products include Tedopi that is in Phase III clinical trial for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; OSE-279, which is in a Phase I/II clinical trial in patients with advanced solid tumors or lymphomas; OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; and FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis. The company is also developing BI 765063, which is in Phase I clinical trial to treat solid tumors; ABBV-230, an agonist antibody against ChemR23 to resolve chronic inflammation; and CLEC-1, a therapeutic target in immune-oncology and identified monoclonal antibody antagonists; and BiCKI, a new technology of bispecific checkpoint inhibitors targeting the PD1 receptor and other innovative targets. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, ARCAGY-GINECO, Foundation FoRT, and Nantes University Hospital; and Boehringer Ingelheim, MabSilico, CKD, Servier, Veloxis Pharmaceuticals, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA was founded in 2012 and is headquartered in Nantes, France.
OSE IMMUNOTHERAPE.EO -20 management
9- Mr. Marc Le BozecCEO & Director · born 1969
- Mr. Thomas GidoinDeputy CEO & CFO · born 1983
- Ms. Aurore MorelloChief Scientific Officer
- Dr. Alain Chatelin M.D.Medical Director
- Bérangère Vasseur M.D.Chief Medical Officer Immuno-Oncology
- Mr. Julien PerrierChief Commercial Officer
- Ms. Linda Lebon M.Sc.Chief Regulatory Officer · born 1967
- Dr. Silvia Comis M.D.Chief Clinical & Medical Research Officer
- Mr. Jean-Jacques A.P. Mention Ph.D.Chief Business Officer